Biolux Research announces appointment of vice president of Global Sales and Marketing
Vancouver, Canada—March 5, 2014—Biolux Research, the developer of light Accelerated Orthodontics technology and products, is pleased to announce the key appointment of orthodontic industry veteran John Nabors as Vice President of Global Sales and Marketing. Mr. Nabors’ primary responsibility is the commercialization of the OrthoPulse, a new product developed to significantly accelerate orthodontic tooth movement and reduce treatment timelines. The OrthoPulse product is planned for commercial soft-launch in mid-2014 in select target markets within Canada and Europe, followed by introduction into other markets.
Mr. Nabors has dedicated his career to the continued growth and development of the orthodontic profession. He has extensive global orthodontic industry leadership experience, including 25 years with 3M Unitek and advancing to the positions of Director of Sales, Western Region and Director of Global Educational Marketing. He was involved with customer focus groups, product development evaluations, and the successful launch of Transcend, APC, Clarity, MBT System, Forsus, and Imtech temporary anchorage devices that produced game changing orthodontic techniques. Following 3M Unitek, he was recruited to Ortho Technologies as Senior Vice President of Global Sales, where he implemented a complete marketing and sales restructuring that contributed to the acquisition of Ortho Technologies by Henry Schein. Most recently, Mr. Nabors was the Director of US Sales at TP Orthodontics, where he restructured the sales team and process with veteran regional sales management leadership, and improved operational profits by reducing aggressive pricing. Specifically, he executed on a consultative value selling process which integrated the voice of the customer, market and competitive analysis, product improvement, commercialization strategy, marketing, sales training, and an effective US sales plan.
“I am excited to join Biolux and have the opportunity to commercialize this game-changing orthodontic technology,” states Mr. Nabors. “The clinical results to date are very promising, and indicate a significant reduction of orthodontic treatment time by as much as 50%. The market is motivated for this type of innovation. I look forward to applying my industry experience, relationships and energy to the opportunities ahead. I’m confident, after meeting with the Biolux advisory board and the executive leadership team, that OrthoPulse will be a revolutionary solution to significantly reducing orthodontic treatment.”
“We are delighted to welcome John to our team and feel that his global expertise and relationships in the orthodontic industry will lead to successful commercialization of our OrthoPulse product and technologies,” states Kevin Strange, President and CEO of Biolux Research. “We are confident that 2014 is going to be a very exciting year for Biolux, and we look forward to significantly reducing treatment timelines for orthodontic patients and orthodontists.”